Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC

NCT03994744 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

68

Enrollment

OTHER

Sponsor class

Conditions

Small-cell Lung Cancer
Small Cell Lung Carcinoma
Small Cell Lung Cancer Recurrent
Small Cell Lung Cancer Extensive Stage

Interventions

DRUG: PD-1 inhibitor
DRUG: Metformin

Sponsor

Hunan Cancer Hospital

Collaborators

[object Object]
[object Object]